Related Experiment Videos
Selection bias in clinical trials with antipsychotics.
1Department of Biological Psychiatry, University Clinics Innsbruck, Austria. Birgit.Mader@uibk.ac.at
Journal of Clinical Psychopharmacology
|December 6, 2000
Summary
Patient selection for antipsychotic clinical trials significantly impacts results. Eligible schizophrenia patients were often excluded due to noncompliance or consent refusal, questioning study representativeness.
Area of Science:
- Psychiatry
- Clinical Trials
- Schizophrenia Research
Background:
- Patient selection is crucial in clinical trials, yet recruitment issues remain understudied.
- Many schizophrenia patients screened for antipsychotic trials are not included, raising concerns about generalizability.
Purpose of the Study:
- To investigate reasons for selective sampling in schizophrenia patients undergoing clinical trials.
- To determine if recruited patients represent the broader schizophrenia population.
Main Methods:
- Analysis of 200 consecutively admitted schizophrenia patients over 33 months.
- Collected demographic data, psychopathology ratings (Brief Psychiatric Rating Scale), and inclusion/eligibility status for a phase III trial.
Main Results:
- Only 27 patients were recruited for the clinical trial.
- Recruited patients were younger, had earlier illness onset, and fewer prior psychotic episodes.
- Noncompliance with prior treatment and refusal of consent were primary exclusion reasons for eligible patients.
Conclusions:
- Schizophrenia clinical trial participants may not fully represent the general patient population.
- Noncompliance and consent refusal are significant barriers to recruitment, impacting trial generalizability.